Evolocumab对后续心肌梗死类型和大小的影响:FOURIER随机临床试验的预设分析
Evolocumab显著降低首次心梗风险27%,主要降低1型和4型心梗,对2型无影响,且无论心梗大小及STEMI与否均一致获益。
要点
- Evolocumab降低首次心梗风险27%,1型降32%,4型降35%,2型无影响。
- 肌钙蛋白≥10倍正常上限的心梗降34%,STEMI风险降36%。
- 获益与心梗大小和类型(STEMI与非STEMI)一致,支持强化降脂。
核心结论
- Evolocumab降低LDL-C可有效减少心梗风险,且获益涵盖斑块破裂相关多种亚型、不同大小及STEMI与非STEMI。
主要发现
- 1,107例患者发生1,288次心梗,68%为1型,15%为2型,15%为4型,3型和5型共21次(<2%)。
- Evolocumab降低首次心梗风险27%(4.4% vs 6.3%;HR 0.73;95%CI 0.65-0.82;P<.001)。
- Evolocumab降低1型心梗32%(2.9% vs 4.5%;HR 0.68;95%CI 0.59-0.79;P<.001)。
- Evolocumab降低4型心梗35%(0.8% vs 1.1%;HR 0.65;95%CI 0.48-0.87;P=.004),对2型无影响(0.9% vs 0.8%;HR 1.09;95%CI 0.82-1.45;P=.56)。
- 肌钙蛋白≥10倍正常上限的心梗降低34%(2.6% vs 3.7%;HR 0.66;95%CI 0.56-0.77;P<.001),STEMI风险降低36%(1.0% vs 1.5%;HR 0.64;95%CI 0.49-0.84;P<.001)。
关键数值与推荐
- 心梗定义基于第三版全球心梗定义,按通用分型(1-5型)及STEMI与非STEMI分类,并按肌钙蛋白峰值确定大小。
- 主要终点率以3年Kaplan-Meier估计表示。
临床怎么用
- 对于接受他汀治疗的稳定性动脉粥样硬化患者,加用evolocumab可显著降低1型、4型及较大/STEMI心梗风险,临床可考虑强化降LDL-C以进一步减少心梗事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored. OBJECTIVE: To assess the types and sizes of myocardial infarction (MI) and the effect of evolocumab on MI by subtype. DESIGN, SETTING, AND PARTICIPANTS: A prespecified analysis of a multicenter double-blind randomized clinical trial. Patients were randomized to evolocumab or placebo and followed up for a median of 2.2 years. The study included 27 564 patients with stable atherosclerotic disease receiving statin therapy. Clinical end points were evaluated by the Thrombolysis in Myocardial Infarction clinical events committee. Rates presented are 3-year Kaplan-Meier estimates. Data were collected from 2013 to 2016 and analyzed from June 2017 to December 2019. MAIN OUTCOMES AND MEASURES: Myocardial infarction was defined based on the third universal MI definition, and further classified according to MI type (universal MI subclass, ST-segment elevation myocardial infarction [STEMI] vs non-STEMI) and by MI size (determined by peak troponin level). RESULTS: A total of 27 564 patients were randomized, with a mean (SD) age of 62.5 (9.0) years, and 20 795 (75%) were male. Of these, 1107 patients experienced a total of 1288 MIs. Most MIs (68%) were atherothrombotic (type 1), with 15% from myocardial oxygen supply-demand mismatch (type 2) and 15% percutaneous coronary intervention-related (type 4). Sudden death (type 3) and coronary artery bypass grafting-related (type 5) accounted for a total of 21 MIs (<2%). Evolocumab significantly reduced the risk of first MI by 27% (4.4% vs 6.3%; hazard ratio [HR], 0.73; 95% CI, 0.65-0.82; P < .001), type 1 by 32% (2.9% vs 4.5%; HR, 0.68; 95% CI, 0.59-0.79; P < .001), and type 4 by 35% (0.8% vs 1.1%; HR, 0.65; 95% CI, 0.48-0.87; P = .004), with no effect on type 2 (0.9% vs 0.8%; HR, 1.09; 95% CI, 0.82-1.45; P = .56). Most MIs (688 [59.8%]) had troponin levels greater than or equal to 10 times the upper limit of normal. The benefit was highly significant and consistent regardless of the size of MI with a 34% reduction in MIs with troponin level greater than or equal to 10 times the upper limit of normal (2.6% vs 3.7%; HR, 0.66; 95% CI, 0.56-0.77; P < .001) and a 36% reduction in the risk of STEMI (1.0% vs 1.5%; HR, 0.64; 95% CI, 0.49-0.84; P < .001). CONCLUSIONS AND RELEVANCE: Low-density lipoprotein cholesterol lowering with evolocumab was highly effective in reducing the risk of MI. This reduction with evolocumab included benefit across multiple subtypes of MI related to plaque rupture, smaller and larger MIs, and both STEMI and non-STEMI. These data are consistent with the known benefit of low-density lipoprotein cholesterol lowering and underscore the reduction in clinically meaningful events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01764633.
引用
- Wiviott SD, Giugliano RP, Morrow DA, et al. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2020. PMID: 32347885. doi:10.1001/jamacardio.2020.0764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。